Built to Drive / Driven To Cure
 
 

DTC Mission

"Help raise awareness and provide funding
for the research of rare kidney cancers like HLRCC
in children and young adults."

 

“I am personally experiencing the effects of rare kidney cancer (HLRCC) and I have seen the effects on others who are also being treated. More research is needed to help them and their families so institutions (like National Cancer Institute at NIH, Yale Smilow Cancer Center, Georgetown Lombardi Cancer Center, and David Geffen School of Medicine at UCLA) can continue to help those who suffer from rare kidney cancers. With this continued collaboration from these institutions, we are growing closer to new cures.”
-Andrew Lee

 

Please find our collection of HLRCC specific information and links at the bottom of this page.
We will be updating this constantly as we come across more ground breaking research.



BOARD MEMBERS

Andrew H. Lee, Director, 
President & CEO, Driven to Cure, INC
Bruce H. Lee, Director, 
Chairman, Treasurer & Secretary of Driven to Cure, (President & CEO, LDG INC)
Daniel J. Bihlmeyer, Director,
(North America Marketing Director,
BASF Automotive Refinish)

Patrick F. Greaney, Director,
(Attorney, Furey, Doolan & Abell, LLP)
James P. Martinko, Director,
(Office Managing Partner CPA, CohnReznick LLP)
Harvey Goodman, Director,
(President, Goodman-Gable-Gould)
Kenneth R. Kennerly, Director,
(Executive Director The Honda Classic)
Ronald D. Paul, Director,
(Chairman/CEO EagleBank) 

IT & Marketing Support
Max Vandenberg
Photography & Video
Tommy F. Lee (Crustless Media)

FCancerBASF2.jpg
20161102_115648.jpg
received_1315671795112666.jpeg
20161005_214828.jpg
 

HLRCC Specific Information and Links

HLRCC - A rare inherited disorder that increases the risk of developing benign (not cancer) lesions of the skin and the uterus (leiomyomas) and malignant (cancer) tumors of the uterus (leiomyosarcoma) and the kidney. Also called hereditary leiomyomatosis and renal cell cancer syndrome.